PUNCTAL PLUG WITH ACTIVE AGENT

• US 20170172916A1
• Filed: 02/08/2017
• Published: 06/22/2017
• Est. Priority Date: 04/15/2004
• Status: Active Application

• Current Assignee: Mati Therapeutics, Inc
• Original Assignee: Mati Therapeutics, Inc
• Inventors: Odrich, Steven A., Glazer, Liane C.
• Application Number:
  US15/427,578
• Publication Number:
  US 20170172916A1
• Time in Patent Office: Days
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61F 9/007 Methods or devices for eye surgery
• CPC Class Codes: A61F 9/00772 Apparatus for restoration of tear ducts
• CPC Class Codes: A61K 31/5575 having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
• CPC Class Codes: A61K 38/13 Cyclosporins
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants

Abstract

A method and apparatus for administering an active agent such as a medicine to a subject, uses an ocular implant such as a punctal plug, to which the active agent has been applied. The implant is installed at the eye of the subject for administering the active agent via tissues of the eye.

Claims

1-19. -19. (canceled)

20. A method for administering an active agent to a subject using a punctal plug, the method comprising:

inserting the punctal plug into a punctal aperture wherein the punctal plug is placed in a vertical portion of a canaliculus proximal to the punctal aperture of an eye of the subject, wherein the composition of the punctal plug comprises;

a) an active agent, and

b) a polymer,

wherein the shape of the punctal plug consists of a constant diameter cylinder.

21. The method of claim 20, wherein the active agent is selected from the group consisting of topical prostaglandin;

latanoprost;

travoprost;

bimatoprost;

a medication for treatment of a corneal infection;

ciprofloxacin;

moxifloxacin;

gatifloxacin;

a systemic medication;

a medication for treating hypertension;

atenolol;

nifedipine;

hydrochlorothiazide; and

a medication for treating allergic conjunctivitis.

22. The method of claim 20, wherein the active agent is cyclosporine.

23. The method of claim 20, wherein the active agent is a medication for treatment of dry eye.

24. The method of claim 20, wherein the active agent is a medication for the topical treatment of glaucoma or corneal infection.

25. The method of claim 20, wherein the polymer is a hydrophilic polymer.

26. The method of claim 20, wherein the polymer is porous or absorbent.

27. The method of claim 20, wherein the active agent is travoprost or a systemic medication.

28. A punctal plug comprising:

a) an active agent, and

b) a polymer,

wherein the shape of the punctal plug consists of a constant diameter cylinder configured to be inserted into a punctal aperture and placed in a vertical portion of a canaliculus proximal to the punctal aperture of an eye.

29. The punctal plug of claim 28, wherein the active agent is selected from the group consisting of topical prostaglandin;

latanoprost;

travoprost;

bimatoprost;

a medication for treatment of a corneal infection;

ciprofloxacin;

moxifloxacin;

gatifloxacin;

a systemic medication;

a medication for treating hypertension;

atenolol;

nifedipine;

hydrochlorothiazide; and

a medication for treating allergic conjunctivitis

30. The punctal plug of claim 28, wherein the active agent is cyclosporine.

31. The punctal plug of claim 28, wherein the active agent is a medication for treatment of dry eye.

32. The punctal plug of claim 28, wherein the active agent is a medication for the topical treatment of glaucoma or corneal infection.

33. The punctal plug of claim 28, wherein the polymer is a hydrophilic polymer.

34. The punctal plug of claim 28, wherein the polymer is porous or absorbent.

35. A punctal plug inserted into a punctal aperture and placed in a vertical portion of a canaliculus proximal to the punctal aperture of an eye comprising:

a) an active agent, and

b) a polymer,

wherein the shape of the punctal plug consists of a constant diameter cylinder.

36. The punctal plug of claim 35, wherein the active agent is selected from the group consisting of topical prostaglandin;

latanoprost;

travoprost;

bimatoprost;

a medication for treatment of a corneal infection;

ciprofloxacin;

moxifloxacin;

gatifloxacin;

a systemic medication;

a medication for treating hypertension;

atenolol;

nifedipine;

hydrochlorothiazide; and

a medication for treating allergic conjunctivitis.

37. The punctal plug of claim 35, wherein the active agent is cyclosporine.

38. The punctal plug of claim 35, wherein the active agent is a medication for treatment of dry eye.

39. The punctal plug of claim 35, wherein the active agent is a medication for the topical treatment of glaucoma or corneal infection.

40. The punctal plug of claim 35, wherein the polymer is a hydrophilic polymer.

41. The punctal plug of claim 35, wherein the polymer is porous or absorbent.